Guggenheim Capital’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-5,257
| Closed | -$994K | – | 1707 |
|
|
2025
Q4 | $994K | Buy |
+5,257
| New | +$1.01M | 0.01% | 950 |
|
|
2024
Q3 | – | Sell |
-5,283
| Closed | -$445K | – | 1911 |
|
|
2024
Q2 | $445K | Sell |
5,283
-1,486
| -22% | -$118K | ﹤0.01% | 1486 |
|
|
2024
Q1 | $495K | Sell |
6,769
-2,123
| -24% | -$157K | ﹤0.01% | 1480 |
|
|
2023
Q4 | $635K | Buy |
8,892
+2,032
| +30% | +$120K | ﹤0.01% | 1357 |
|
|
2023
Q3 | $411K | Sell |
6,860
-404
| -6% | -$26.6K | ﹤0.01% | 1517 |
|
|
2023
Q2 | $524K | Buy |
7,264
+344
| +5% | +$25.8K | ﹤0.01% | 1450 |
|
|
2023
Q1 | $509K | Buy |
6,920
+545
| +9% | +$38.7K | ﹤0.01% | 1487 |
|
|
2022
Q4 | $426K | Sell |
6,375
-3,020
| -32% | -$196K | ﹤0.01% | 1554 |
|
|
2022
Q3 | $505K | Buy |
9,395
+5,041
| +116% | +$296K | ﹤0.01% | 1480 |
|
|
2022
Q2 | $243K | Buy |
+4,354
| New | +$247K | ﹤0.01% | 1867 |
|
|
2020
Q4 | – | Sell |
-37,919
| Closed | -$2.25M | – | 2084 |
|
|
2020
Q3 | $2.25M | Buy |
37,919
+148
| +0.4% | +$10.1K | 0.02% | 842 |
|
|
2020
Q2 | $2.64M | Buy |
37,771
+888
| +2% | +$56.3K | 0.02% | 764 |
|
|
2020
Q1 | $1.67M | Sell |
36,883
-4,819
| -12% | -$273K | 0.02% | 870 |
|
|
2019
Q4 | $2.71M | Buy |
41,702
+7,138
| +21% | +$477K | 0.02% | 916 |
|
|
2019
Q3 | $2.15M | Sell |
34,564
-3,863
| -10% | -$243K | 0.02% | 979 |
|
|
2019
Q2 | $2.74M | Sell |
38,427
-4,083
| -10% | -$301K | 0.02% | 919 |
|
|
2019
Q1 | $3.33M | Sell |
42,510
-8,095
| -16% | -$613K | 0.03% | 833 |
|
|
2018
Q4 | $4.28M | Buy |
50,605
+8,218
| +19% | +$876K | 0.04% | 649 |
|
|
2018
Q3 | $7.26M | Buy |
42,387
+5,571
| +15% | +$840K | 0.05% | 497 |
|
|
2018
Q2 | $4.76M | Sell |
36,816
-20,272
| -36% | -$2.26M | 0.03% | 754 |
|
|
2018
Q1 | $5.88M | Sell |
57,088
-3,390
| -6% | -$335K | 0.01% | 919 |
|
|
2017
Q4 | $5.17M | Sell |
60,478
-2,429
| -4% | -$211K | 0.01% | 1019 |
|
|
2017
Q3 | $5.34M | Buy |
62,907
+2,745
| +5% | +$217K | 0.01% | 1021 |
|
|
2017
Q2 | $4.56M | Sell |
60,162
-117
| -0.2% | -$8.19K | 0.01% | 1075 |
|
|
2017
Q1 | $3.98M | Buy |
60,279
+1,106
| +2% | +$72.8K | 0.01% | 1162 |
|
|
2016
Q4 | $3.75M | Sell |
59,173
-41,434
| -41% | -$2.61M | 0.01% | 1187 |
|
|
2016
Q3 | $6.41M | Sell |
100,607
-5,149
| -5% | -$378K | 0.02% | 878 |
|
|
2016
Q2 | $7.87M | Sell |
105,756
-9,921
| -9% | -$736K | 0.02% | 776 |
|
|
2016
Q1 | $7.73M | Sell |
115,677
-35,101
| -23% | -$2.13M | 0.02% | 801 |
|
|
2015
Q4 | $10.2M | Sell |
150,778
-5,343
| -3% | -$330K | 0.03% | 748 |
|
|
2015
Q3 | $8.34M | Sell |
156,121
-32,677
| -17% | -$1.98M | 0.03% | 822 |
|
|
2015
Q2 | $11.9M | Buy |
188,798
+14,645
| +8% | +$799K | 0.03% | 772 |
|
|
2015
Q1 | $8.38M | Sell |
174,153
-874
| -0.5% | -$33.5K | 0.02% | 930 |
|
|
2014
Q4 | $5.81M | Buy |
175,027
+4,423
| +3% | +$144K | 0.01% | 1051 |
|
|
2014
Q3 | $5M | Buy |
170,604
+66,730
| +64% | +$2.22M | 0.01% | 1195 |
|
|
2014
Q2 | $4.04M | Sell |
103,874
-16,877
| -14% | -$685K | 0.01% | 1316 |
|
|
2014
Q1 | $5.07M | Sell |
120,751
-17,069
| -12% | -$711K | 0.01% | 1117 |
|
|
2013
Q4 | $4.52M | Buy |
+137,820
| New | +$4.49M | 0.01% | 1145 |
|
Other funds holding LGND
VPM
VCM
NAMI
CC
Guggenheim Capital's LGND Position: Q1 2026 in Review
Guggenheim Capital sold out of Ligand Pharmaceuticals (LGND) in Q1 2026, closing a stake of 5,257 shares — an estimated $994K sold.
Guggenheim Capital first reported a position in LGND in Q4 2013 and held it in 38 quarters. The position peaked at $11.9M in Q2 2015. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.
- Guggenheim Capital reported no remaining Ligand Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Guggenheim Capital sold 5,257 Ligand Pharmaceuticals shares in Q1 2026, an estimated $994K.
- Guggenheim Capital first reported a position in Ligand Pharmaceuticals in Q4 2013 and held it in 38 quarters.
- Guggenheim Capital's Ligand Pharmaceuticals position peaked at $11.9M in Q2 2015.
- 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.
Based on Guggenheim Capital's 13F filing for Q1 2026, filed 15 May 2026.